Half remain ADT-free two years after repeated PSMA-guided prostate metastasis-directed radiotherapy
After a second PSMA-guided metastasis-directed RT course, 50.2% of 177 oligorecurrent prostate cancer patients remained ADT-free at two years.
After a second PSMA-guided metastasis-directed RT course, 50.2% of 177 oligorecurrent prostate cancer patients remained ADT-free at two years.
In 72 matched pairs, initial local therapy without systemic treatment was associated with 73.0% versus 58.6% five-year survival, without improved PFS.
SABR achieved 92.5% one-year local control in oligometastatic breast cancer, while pooled randomized evidence did not definitively establish a PFS benefit.
SBRT can provide high local control in selected oligometastatic pancreatic cancer, but randomized survival evidence and patient-selection criteria remain limited.
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
Longer survival after metastasis-directed therapy is creating unmet physical, psychological and functional needs that conventional surveillance pathways may not adequately address.
Two-year local control reached 88%, but median progression-free survival was 5.8 months and systemic treatment changed after 4.4 months.